Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Lucas M KimmigChuanhong LiaoRemzi BagPublished in: Lung (2020)
For select patients, transition from a parenteral prostanoid-based therapy to a combination regimen including inhaled treprostinil in the home setting appears safe and well tolerated.
Keyphrases
- pulmonary arterial hypertension
- pulmonary artery
- pulmonary hypertension
- end stage renal disease
- cystic fibrosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- blood pressure
- peritoneal dialysis
- prognostic factors
- stem cells
- coronary artery
- mesenchymal stem cells
- bone marrow
- patient reported outcomes
- cell therapy
- patient reported